Status:
COMPLETED
The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Lead Sponsor:
Pfizer
Conditions:
Pancreatic Neuroendocrine Tumors
Eligibility:
All Genders
18+ years
Brief Summary
This study is a multi-center, prospective, non-interventional (NI) study evaluating the safety and efficacy of sunitinib in Chinese patients with progressive, unresectable, advanced or metastatic well...
Detailed Description
The sunitinib non-interventional (NI) study is a real world observational study which represents the usual and customary treatment of patients and being proposed to collect data systematically and to ...
Eligibility Criteria
Inclusion
- Evidence of a personally signed and dated informed consent document indicating that the subject (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
- Subjects who are willing to follow up visits within current clinical practice.
- Histologically or cytologically proven diagnosis of well-differentiated pancreatic neuroendocrine tumors (according to WHO 2000 classification)
- Unresectable (as assessed by the investigator) or metastatic disease documented on a scan
- A minimum age of 18 years
Exclusion
- Patients with poorly-differentiated pancreatic neuroendocrine tumors (according to WHO 2000 classification)
- Patients who have received at least one dosage of sunitinib treatment prior to signing informed consent form will be excluded from participating in this study.
Key Trial Info
Start Date :
December 12 2014
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 12 2022
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT02282059
Start Date
December 12 2014
End Date
December 12 2022
Last Update
June 20 2024
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Oncology Department, The Second Affiliated Hospital of Anhui Medical University
Hefei, An'hui, China, 230061
2
Department of Medical Oncology, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, China, 100021
3
SUN Yat-Sen University Cancer Center
Guangzhou, Guangdong, China, 510060
4
The Affiliated Tumour Hospital of Harbin Medical University
Haerbin, Heilongjiang, China, 150081